DarlaKLilesMD

Oncology • Greenville, NC

Hematologic Oncology

Professor of Medicine, E Carolina University

Join to view full profile

Dr. Liles is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liles' full profile

Already have an account?

Office
600 Moye Blvd
Greenville, NC 27834
Phone+1 252-744-4676

Fax+1 252-744-3194

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1990 - 1994
ECU Health Medical Center/East Carolina UniversityInternship, Internal Medicine, 1986 - 1990
University of Missouri Kansas City School of MedicineClass of 1986

Certifications & Licensure

NC State Medical License 1990 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
Completed
Phase 3
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Start of enrollment: 2017 Apr 11
Completed
Phase 2
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2018 Nov 01
Completed
Phase 3
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy Start of enrollment: 2021 Jun 02
Terminated
Phase 3
Roles: Contact, Principal Investigator
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease Start of enrollment: 2019 Oct 21
Completed
Phase 1
Roles: Principal Investigator
Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications Start of enrollment: 2020 Aug 12
Completed
Not Applicable
Roles: Contact
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Start of enrollment: 2023 Mar 21
Recruiting
Phase 2
Roles: Principal Investigator
AB1 in Adult Patients With Sickle Cell Disease (SCD) Start of enrollment: 2022 Dec 05
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.
Ayotola Fatola, Michael D Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson
Blood Advances. 2025-01-28
The use of abstract animations and a graphical body image for assessing pain outcomes among adults with sickle cell disease.
Julia A O'Brien, Charles R Jonassaint, Ektha Parchuri, Christina M Lalama, Sherif M Badawy
The Journal of Pain. 2025-01-01
Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease.
Charles R Jonassaint, Christina M Lalama, C Patrick Carroll, Sherif M Badawy, Megan E Hamm
Blood Advances. 2024-12-24

Journal Articles

Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
Muzaffar M1, Jia J, Liles D, Naveed M, Kumari A., Am J Ther., 1/7/2014

Abstracts/Posters

The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study
Darla K Liles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies
Darla K Liles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study
Darla K Liles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura
Darla K Liles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations
Darla K Liles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

East Carolina University: CANCER CLINICAL TRIALSJuly 29th, 2021
Vidant EastCare Becomes One of First Flight Programs in State to Carry O Negative Whole BloodJune 2nd, 2021
Financial Barriers Stand in the Way of Research at Rural HospitalsApril 13th, 2021
Join now to see all